Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
The patient was supposed to get her second dose of RABAVERT on April 23rd, but she never got it.; Case reference number US-BN-2025-000886 is a spontaneous case initially received from pharmacist via Med Communication (reference number: USBAV25-0963) on 29-Apr-2025 and concerns an adult female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On unspecified date, the patient received the first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route or site of administration for indication post-exposure vaccination. As reported, the patient was supposed to get her second dose of RabAvert on April 23rd, but she never got it (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to RabAvert. No further information was provided.; Reporter's Comments: An adult female patient of unspecified age received the first dose of RabAvert for indication post-exposure vaccination. As reported, the patient was supposed to get her second dose of RabAvert on April 23rd, but she never got it, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any of adverse events due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An adult female patient of unspecified age received the first dose of RabAvert for indication post-exposure vaccination. As reported, the patient was supposed to get her second dose of RabAvert on April 23rd, but she never got it, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any of adverse events due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None